Respiratory
Pipeline

Lungs

About our Respiratory Diseases efforts

We are building on a heritage of more than a century in respiratory diseases, with treatments in asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrotic interstitial lung diseases. Our R&D approach leverages our deep understanding and extensive expertise in respiratory medicine, inflammation and fibrosis to develop the next generation of innovative therapies for patients with a broad range of lung diseases who have a high unmet medical need.

Read more about Nerandomilast (BI 1015550): PDE4B inhibitor

Respiratory

Idiopathic pulmonary fibrosis

PDE4B inhibitor

Nerandomilast (BI 1015550)

Read more about Nerandomilast (BI 1015550): PDE4B inhibitor

Respiratory

Progressive pulmonary fibrosis

PDE4B inhibitor

Nerandomilast (BI 1015550)

Read more about Ion channel inhibitor

Respiratory

Ion channel inhibitor

Read more about Lysophospholipase inhibitor

Respiratory

Idiopathic/progressive pulmonary fibrosis

Lysophospholipase inhibitor

BI 1819479

Read more about BI 1291583: CatC Inhibitor

Respiratory

Non-cystic fibrosis bronchiectasis

CatC inhibitor

BI 1291583

Read more about IL11 antibody

Respiratory

IL11 antibody

Read more about Oxidase Inhibitor

Respiratory

Oxidase Inhibitor

Read more about Anti-fibrotic agent

Respiratory

Anti-fibrotic agent